Connect with us

Technology

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Published

on

WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ — COEPTIS, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million. This significant achievement highlights investor confidence in Coeptis’ innovative therapeutic solutions and its strategic pivot towards technology-driven growth.

The financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise, through an increase in their initial investment in the round. Under the terms of the latest financing, the Series A Preferred is convertible into shares of the Company’s common stock at a price of $8.00 per share, subject to limitations. Additionally, investors received an aggregate 15% equity interest in the Company’s newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. This announcement follows an initial closure of $4.3 million in June 2024.

“We’re thrilled to announce the successful closure of our second Series A Preferred financing,” said Brian Cogley, CFO of COEPTIS. “This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division. The integration of AI-driven tools, particularly from our recent acquisition of the NexGenAI Affiliates Network platform, is vital in revolutionizing our approach to marketing and operational efficiencies in the highly regulated biopharmaceutical sector.”

The proceeds from this financing will be utilized to strengthen the Company’s balance sheet, repay outstanding obligations, and support general corporate purposes, alongside the $4.3 million already raised. Moreover, the additional capital will accelerate Coeptis’ ongoing integration of advanced AI solutions and automation capabilities, enhancing not only research processes but also the overall operational framework of the Company.

“This additional financing enables Coeptis to not just fortify its mission in cell therapy but also empowers us to drive innovation in technology and AI,” added Dave Mehalick, President and CEO of COEPTIS. “By fostering a culture of responsible innovation, we aim to capitalize on diverse growth opportunities, creating a self-sustaining business model that establishes a strong foundation for long-term success and profitability.”

About COEPTIS, Inc.

COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively “Coeptis”), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.

The Company’s therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.

Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.

Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of our management made in connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company’s securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company’s products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

Contacts
IR@coeptistx.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-completes-10-million-series-a-preferred-financing-round-reinforcing-commitment-to-technological-innovation-and-ai-integration-302369957.html

SOURCE Coeptis Pharmaceuticals, Inc.

Continue Reading

Technology

dxFeed Introduces ZeroDTE to Bring Greater Transparency to 0DTE Trading Risk

Published

on

By

NEW YORK, Oct. 20, 2026 /PRNewswire/ — dxFeed, a global provider of market data and financial technology solutions, introduced dxFeed ZeroDTE, a new quantitative analytics solution designed to bring greater transparency and precision to the rapidly growing market for zero-days-to-expiration (0DTE) options.

Developed by dxFeed’s AI & Quant Research team, the solution transforms live SPX and XSP options data into comprehensive pricing and risk analytics, enabling brokers, trading platforms, and analytics providers to give traders a clearer understanding of potential outcomes before entering a trade.

The introduction comes as 0DTE options continue to reshape US derivatives markets. According to Cboe, same-day contracts accounted for approximately 65%* of SPX options trading volume in Q3 2026, averaging a record 3.2 million contracts daily. Yet the analytical tools available to traders have not always kept pace with this growth, particularly when it comes to understanding the risks behind complex, multi-leg strategies — a challenge previously highlighted by Jon Light, Senior Director of Product Management, Devexperts.

Beyond Probability of Profit: Understanding the Full Risk
While conventional trading interfaces typically display strikes, premiums, and margin requirements, ZeroDTE reveals the market-implied probabilities behind each strategy, including the likelihood of retaining the full premium, experiencing a partial loss, or reaching the maximum possible loss.

Unlike traditional probability calculations based on a single implied volatility estimate or delta, the solution analyzes the entire live options chain, incorporating the volatility smile and distribution tails to deliver a consistent view of market-implied outcomes.

Through a single API integration, platforms can provide traders with:

Market-implied probabilities of different profit and loss outcomes.Fair value comparisons against displayed market prices.Maximum profit, maximum loss, and break-even levels for individual strategies.Market-implied distribution of today’s close, derived from live options data.Strategies defined in units of the day’s priced move, so the same structure can be compared across days and market conditions .

Supporting popular structures including iron condors, butterflies, straddles, strangles, and vertical spreads, the service brings sophisticated quantitative analytics directly into the trading experience.

“Retail platforms are good at showing a probability of profit, and most will show the maximum loss as well. What they don’t show is how likely that loss is,” said Anton Antonov, Head of AI & Quant Research at dxFeed. “ZeroDTE puts the odds next to the worst case: the chance of keeping the credit, of a partial loss and of the maximum loss, read from the whole option chain rather than a single volatility number. Rather than predicting where the market will go, we give traders the tools to understand what current options prices imply, evaluate different strategies consistently, and make more informed decisions.”

Expanding dxFeed’s Intelligent Market Data Ecosystem
ZeroDTE marks another milestone in dxFeed’s evolution from market data delivery toward advanced analytics, quantitative research, and intelligent financial technology.

The solution joins dxFeed’s growing portfolio of innovative technologies, including SummerFox, its award-winning AI-powered market intelligence solution; Grenadier, an AI-based market data anomaly detection technology; and dxScript, an AI-assisted scripting environment for custom market analytics and indicators.

Together, these solutions reinforce dxFeed’s commitment to transforming high-quality financial data into accessible, actionable intelligence for the global trading community.

The new analytics capabilities have already been integrated into DXcharts, demonstrating how advanced options risk metrics can be incorporated directly into trading and charting interfaces.

For a deeper look at the technical capabilities, key features, and practical applications of ZeroDTE, explore our in-depth article.

*All figures are market-implied from current option prices and are not a forecast or a recommendation

Media Contact:
Kate Zapekina
+49 8999 952020
425091@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dxfeed-introduces-zerodte-to-bring-greater-transparency-to-0dte-trading-risk-302913870.html

SOURCE dxFeed

Continue Reading

Technology

One Third of Florida’s Banks and Credit Unions Not Yet Protected Against Future Quantum Decryption, Open-Source Scan Finds

Published

on

By

Manteiga Foundation publishes a state-of-readiness note on 81 Florida institutions: nothing is broken today, the risk is time, and for most the fix is one setting

MIAMI, Oct. 20, 2026 /PRNewswire/ — Of 81 Florida-headquartered banks and credit unions, 54 already protect their customers’ connections against future quantum decryption and 27 do not yet, according to a state-of-readiness note published today by Manteiga Foundation, a Florida public benefit company. The note, the first from the foundation’s Quantum Ready Labs, lists every institution and its result: quantumreadylabs.com/studies/florida-financial-2026q4.

Nothing is broken today. No account, login or transaction is at risk from what the note describes; every connection tested is encrypted with algorithms no existing computer can break.

The risk is time. Encrypted traffic can be recorded now and decrypted once a large enough quantum computer exists, so anything that must stay confidential for years is already inside the window. That window is narrowing: in 2025 the estimated size of the machine needed to break today’s key exchange fell from about twenty million qubits to under one million, and NIST has set 2030 to begin retiring today’s key exchange and 2035 to end it. Browsers already protect traffic the new way.

The fix is small. The 27 split in two. Ten are Exposed, their sites still on a protocol generation that cannot carry post-quantum protection; the next step is to enable TLS 1.3. Seventeen are At risk, on a modern protocol with the protection not switched on; the next step is one setting, the post-quantum key exchange (X25519MLKEM768), a configuration line or a toggle on current servers. The 54 are Protected (30) or Ready (24). The median score is 85 of 100; the note uses four plain words, no letter grades.

“Nothing is broken today, and that is exactly why this is the moment to act,” said Jaime Manteiga, Co-Founder of Manteiga Foundation. “Confidentiality is the urgent part of the quantum transition, the fix is small, and most of these institutions are one setting away. We built the scanner so that anyone can see where a host stands in a second and what to do next.”

Quantum Ready Labs is free and open source under the MIT licence. Typing a host name at quantumreadylabs.com opens a handful of connections to it, as a browser visit would, and returns the stage, a score for quantum readiness alone, the one next step and the standards cited (NIST IR 8547, FIPS 203, CNSA 2.0), shareable by link or as a five-page PDF; an open API runs the same test for services.

Each institution’s public primary domain was tested on October 18, 2026 with fourteen TLS handshakes and one ordinary connection; no page was opened, no login attempted. Every Exposed result was cross-checked with OpenSSL and curl. The population, from public regulator lists with each domain verified, will be re-scanned quarterly; any institution can run a fresh test at once.

For organizations that want help making the change, the foundation operates N30.ai, its cybersecurity consulting practice. The scanner and its results stay free and open.

About Manteiga Foundation

Manteiga Foundation is a Florida public benefit company at the meeting of technology and art, bringing more beauty into technology through open-source tools for the public good, among them Quantum Ready Labs and medet.ink. manteiga.org.

About N30.ai

N30.ai is Manteiga Foundation’s cybersecurity consulting practice for the post-quantum transition and related security work. More at n30.ai.

Media contact

Jaime Manteiga, Co-Founder, Manteiga Foundation
425109@email4pr.com | 305-709-2909
quantumreadylabs.com/studies/florida-financial-2026q4  |  github.com/manteiga-foundation/quantum-ready-labs

View original content to download multimedia:https://www.prnewswire.com/news-releases/one-third-of-floridas-banks-and-credit-unions-not-yet-protected-against-future-quantum-decryption-open-source-scan-finds-302913890.html

SOURCE Manteiga Foundation

Continue Reading

Technology

CME Group Announces First Trade for Bitcoin Cash and Uniswap Futures

Published

on

By

CHICAGO, Oct. 20, 2026 /PRNewswire/ — CME Group, the world’s leading derivatives marketplace, today announced that FalconX and GSR have executed the first block trade in its new Bitcoin Cash (BCH) and Uniswap (UNI) futures.

“With trading now underway in our Bitcoin Cash and Uniswap futures, we are providing clients with more versatility to manage cryptocurrency risk and exposure through our robust 24/7 marketplace,” said Giovanni Vicioso, Global Head of Cryptocurrency Products at CME Group. “As institutional demand for digital assets continues to grow, we are pleased that investors are turning to CME Group to expand their crypto trading strategies with our regulated and capital-efficient tools.”

“FalconX is pleased to execute the first block trade in CME Group’s new Bitcoin Cash and Uniswap futures alongside GSR. Institutional demand is moving beyond the largest digital assets toward tokens with distinct use cases, like Bitcoin Cash in payments and Uniswap in decentralized finance,” said Griffin Sears, Head of Derivatives, FalconX. “Bringing these assets onto a regulated venue like CME Group gives institutions the hedging and capital-efficient exposure they’ve been asking for, and we look forward to supporting liquidity in these markets as they grow.”

“Providing liquidity in crypto derivatives has long been a cornerstone of GSR’s business, making it a natural fit for us to support CME Group’s new Bitcoin Cash and Uniswap futures from day one,” said Xin Song, CEO of GSR. “We have long believed that expanding institutional-grade derivatives will supercharge institutional adoption of digital assets, and CME Group plays a central role in making that vision a reality.”

The new contracts further extend CME Group’s single-asset cryptocurrency product suite, which includes Bitcoin, Ether, XRP, Solana, Cardano, Chainlink, Stellar, Avalanche‌ and Sui futures. Trading highlights include:

Year-to-date 2026 futures and options average daily volume (ADV) of more than 242,000 contracts ($7.9 billion notional) and average daily open interest (OI) of almost 240,000 contracts ($14.3 billion notional).Nearly $2 billion in year-to-date notional value growth from the 2026 expansion into Cardano, Chainlink, Stellar, Avalanche, and Sui futures.

Bitcoin Cash and Uniswap futures are listed on and subject to the rules of CME. For more information on these products, please visit here.

As the world’s leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals.  The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform.  In addition, it operates one of the world’s leading central counterparty clearing providers, CME Clearing. 

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc.  CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“S&P DJI”). “S&P®”, “S&P 500®”, “SPY®”, “SPX®”, US 500 and The 500 are trademarks of Standard & Poor’s Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners. 

CME-G

View original content:https://www.prnewswire.com/news-releases/cme-group-announces-first-trade-for-bitcoin-cash-and-uniswap-futures-302914023.html

SOURCE CME Group

Continue Reading

Trending